Gregory C. Critchfield, M.D., M.S.
Independent Director, Indi
CEO, Sera Prognostics, Inc.
Dr. Gregory Critchfield is CEO of Sera Prognostics, a private biotechnology company developing novel diagnostic tests for the early prediction of preterm birth and other pregnancy complications. He currently serves as an independent director of Saladax Biomedical, Metamark Genetics and Nodality. Dr. Critchfield is also past President of Myriad Genetic Laboratories, Inc., where he successfully established the company’s medical, scientific, and commercial capabilities beginning in 1998 until he retired in March 2010. During this time, Dr. Critchfield built Myriad Genetic Laboratories into one of the world’s leading molecular diagnostics companies, launching seven novel diagnostics products across multiple technology platforms and growing annual revenues from $2.2 million to $326.5 million.
In the spin-out of Quest Diagnostics, Inc. from Corning Clinical Laboratories, Dr. Critchfield was responsible for innovation and medicine, serving as Quest’s Chief Medical and Science Officer.
From 2007 to 2009, Dr. Critchfield served as an independent Director of BioTrove, a venture-backed molecular biological tools company. In that position he collaborated with Albert A. Luderer, Ph.D., CEO of Indi, who was then BioTrove’s CEO. They worked together at BioTrove until that company was successfully acquired by Life Technologies in December 2009.
In 2007, Dr. Critchfield chaired the Utah Governor’s State Advisory Council on Science and Technology. He served on the Board of the American Clinical Laboratory Association (ACLA).
Earlier in his career Dr. Critchfield worked as a practicing clinical pathologist with Intermountain Healthcare for nine years. Previously, he served as a reviewer and study section chair for the NIH for more than 15 years, working in biomedical computing programs for SBIR, STTR and R01 programs.
Dr. Critchfield’s research has focused on building quantitative models in many areas of laboratory medicine including anticoagulation control, method standardization, mass spectrometric identification of drugs, predictive value modeling, quantitative health policy analysis and clinical genetics. He has served on the faculty of three medical schools: University of Minnesota, Wayne State University and Duke University.
Dr. Critchfield received a Bachelor’s Degree in Microbiology with a minor in Chemistry from Brigham Young University in 1976, an M.D. from the University of Utah in 1980, and a master’s degree in Biophysical Sciences at the University of Minnesota in 1985. He also completed fellowships in Clinical Chemistry and in Health Information Sciences sponsored by the National Library of Medicine and is board certified in Clinical Pathology.